# TARA Biosystems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tara-biosystems

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.tarabiosystems.com
- Total disclosed funding: $21M
- Latest round: Series A (Jun 23, 2020)
- Investors on record: 12

## About

TARA Biosystems, Inc. specializes in advanced cardiovascular disease research utilizing innovative technologies to enhance drug discovery and development, aiming for effective treatment solutions.Founded in 2014 and headquartered in New York, US, TARA Biosystems, Inc. operates to develop therapies for cardiovascular disease. The company was acquired by Valo Health, Inc. in April 2022, which allows for expanded capabilities in drug discovery. The founders, Kacey Ronaldson-Bouchard and Milica Radisic, have backgrounds in biomedical research and entrepreneurship. TARA has completed a Series A funding round, raising USD 10.00 mn with investors including Alexandria Venture Investments and DEFTA Partners, among others.TARA Biosystems, Inc. provides groundbreaking technologies aimed at revolutionizing drug discovery for cardiovascular diseases. Their flagship offerings leverage advanced biological models and data analytics to improve drug efficacy and safety. The company collaborates with pharmaceutical and biotech firms, primarily in North America and Europe, to facilitate efficient drug development processes.TARA's revenue generation is based on B2B partnerships with pharmaceutical companies, enabling clients to utilize their innovative technologies. Clients access TARA's solutions through structured agreements, which may include subscription fees or milestone-based payments tied to project phases, thus facilitating ongoing revenue through these collaborations.Looking ahead, TARA Biosystems, Inc. aims to expand its product offerings and geographic reach. The recent acquisition by Valo Health, Inc. enables TARA to enhance its capabilities in identifying new treatments for cardiovascular diseases, building a comprehensive drug development platform. The funding from the Series A round will support these initiatives, focusing on accelerating the delivery of new therapies to market and exploring opportunities in emerging markets, particularly in Asia-Pacific by the end of 2023.

## Funding rounds

- Series A, Jun 23, 2020, $10M — Alexandria Venture Investments, DEFTA Partners, Merieux Equity Partners, Partnership Fund for New York City, New York Ventures, LifeForce Capital, Trancos Ventures, OMX Ventures, Tachyon Ventures
- Series A, Oct 16, 2017, $9M — Alexandria Venture Investments, 180 Degree Capital, Partnership Fund for New York City, New York Ventures, Morgan Noble, Innovate NY Fund, Trancos Ventures
- Seed, Jan 5, 2016, $2.3M — Alexandria Venture Investments, 180 Degree Capital, Partnership Fund for New York City

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Seed, Series A
- 180 Degree Capital (https://capitalatlas.ai/funds/180-degree-capital) — Seed, Series A
- Partnership Fund for New York City (https://capitalatlas.ai/funds/partnership-fund-for-new-york-city) — Seed, Series A
- New York Ventures (https://capitalatlas.ai/funds/new-york-ventures) — Series A
- Morgan Noble (https://capitalatlas.ai/funds/morgan-noble) — Series A
- Innovate NY Fund — Series A
- Trancos Ventures (https://capitalatlas.ai/funds/trancos-ventures) — Series A
- DEFTA Partners (https://capitalatlas.ai/funds/defta-partners) — Series A
- Merieux Equity Partners (https://capitalatlas.ai/funds/merieux-equity-partners) — Series A
- LifeForce Capital (https://capitalatlas.ai/funds/lifeforce-capital) — Series A
- OMX Ventures (https://capitalatlas.ai/funds/omx-ventures) — Series A
- Tachyon Ventures (https://capitalatlas.ai/funds/tachyon-ventures) — Series A